The abstract is read at the publisher; the summary is JClub's.
Targeted dCas9-based epigenome editing can induce site-specific demethylation and stable reactivation of the silenced maternal 15q11-q13 gene cluster in Prader-Willi syndrome.
- Why it matters: Broad DNA- and histone-methyltransferase inhibitors show limited clinical promise because they lack genomic specificity, motivating precise reactivation of the maternal locus to address hypothalamic dysfunction.
- What they did: The review evaluates high-precision, dCas9-based approaches for demethylating and reactivating the maternal allele, and outlines translational hurdles including CNS delivery, neuronal model validation, and avoiding iatrogenic Angelman syndrome via UBE3A imprinting.
- The result: Progress depends on optimized delivery vectors, advanced human-derived neuronal models to confirm functional recovery, and safety controls to prevent UBE3A misregulation, while alternative targets like epigenetic regulators and non-coding RNAs are proposed.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.